David Baram is a prominent inventor based in Nir Zvi, Israel, known for his significant contributions to the field of biotechnology. With a remarkable portfolio of 9 patents, he demonstrates a commitment to advancing scientific understanding and developing innovative solutions.

Latest Patents

Among his latest patents is a groundbreaking invention titled "Differential knockout of an allele of a heterozygous fibrinogen alpha chain (FGA) gene." This patent involves RNA molecules comprising a guide sequence portion that consists of 17-20 nucleotides and explores compositions, methods, and uses associated with this genetic work. Another noteworthy patent is the "Guide RNA that targets a mutant human inosine monophosphate dehydrogenase I allele," which also includes RNA molecules encompassing a guide sequence portion of 17-20 nucleotides, along with relevant compositions and methods. Both patents emphasize the intricate relationship between genetics and potential therapeutic applications.

Career Highlights

David Baram is affiliated with Emendo Bio Inc., a company focused on innovating DNA and RNA technologies for therapeutic development. His work and research have positioned him as a leader in this cutting-edge field, significantly impacting the future of genetic medicine.

Collaborations

Throughout his career, David has worked alongside talented individuals such as Lior Izhar and Rafi Emmanuel. These collaborations have undoubtedly enhanced his ability to innovate and contribute effectively to the biotechnology community.

Conclusion

David Baram stands out as a remarkable inventor whose patents reflect his dedication to advancing genetic research. His contributions at Emendo Bio Inc. not only underscore his expertise but also highlight the importance of innovation in biotechnology for addressing complex medical challenges.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]